Hims & Hers Health, Inc. (NYSE:HIMS) Receives Consensus Recommendation of “Reduce” from Brokerages

Hims & Hers Health, Inc. (NYSE:HIMS) has received a consensus rating of “Reduce” from the thirteen research firms that are presently covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have issued a buy rating on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $39.58.

A number of analysts recently weighed in on the stock. Wall Street Zen raised shares of Hims & Hers Health from a “hold” rating to a “buy” rating in a report on Sunday, June 15th. TD Cowen cut shares of Hims & Hers Health from a “buy” rating to a “hold” rating and cut their price target for the stock from $44.00 to $30.00 in a research note on Tuesday, April 29th. UBS Group set a $30.00 price target on shares of Hims & Hers Health in a research note on Monday, June 23rd. Truist Financial set a $45.00 price target on shares of Hims & Hers Health in a research note on Tuesday, June 24th. Finally, Citigroup reissued a “sell” rating on shares of Hims & Hers Health in a research note on Monday, June 23rd.

Hims & Hers Health Stock Up 1.0%

HIMS opened at $47.92 on Friday. The company has a market capitalization of $10.72 billion, a price-to-earnings ratio of 69.44, a PEG ratio of 1.74 and a beta of 2.02. The firm has a 50-day moving average price of $51.83 and a 200-day moving average price of $40.09. Hims & Hers Health has a twelve month low of $13.47 and a twelve month high of $72.98.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.08. The firm had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a net margin of 9.24% and a return on equity of 22.75%. The company’s revenue was up 110.7% on a year-over-year basis. During the same quarter last year, the company earned $0.05 earnings per share. On average, sell-side analysts expect that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 65,110 shares of the firm’s stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $59.22, for a total transaction of $3,855,814.20. Following the completion of the sale, the chief executive officer directly owned 95,105 shares in the company, valued at approximately $5,632,118.10. This trade represents a 40.64% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Michael Chi sold 17,102 shares of the firm’s stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $59.75, for a total transaction of $1,021,844.50. Following the sale, the insider owned 278,654 shares of the company’s stock, valued at approximately $16,649,576.50. This represents a 5.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 692,006 shares of company stock worth $34,857,872. 13.71% of the stock is owned by corporate insiders.

Institutional Trading of Hims & Hers Health

A number of large investors have recently made changes to their positions in the stock. Smartleaf Asset Management LLC boosted its holdings in shares of Hims & Hers Health by 15.7% in the first quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company’s stock worth $49,000 after buying an additional 227 shares during the last quarter. Allworth Financial LP lifted its holdings in shares of Hims & Hers Health by 20.0% in the first quarter. Allworth Financial LP now owns 2,006 shares of the company’s stock worth $56,000 after buying an additional 334 shares in the last quarter. Signaturefd LLC increased its position in Hims & Hers Health by 17.7% in the first quarter. Signaturefd LLC now owns 2,586 shares of the company’s stock worth $76,000 after purchasing an additional 388 shares during the last quarter. SlateStone Wealth LLC increased its position in Hims & Hers Health by 4.0% in the fourth quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock worth $257,000 after purchasing an additional 413 shares during the last quarter. Finally, Kilter Group LLC increased its position in Hims & Hers Health by 1.0% during the first quarter. Kilter Group LLC now owns 43,989 shares of the company’s stock valued at $1,300,000 after acquiring an additional 450 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.